IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

BRENTWOOD, Tenn., August 5, 2020 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery...

IMAC Expands Reach to Southwest Florida with Purchase of Established Practice in All Cash Transaction

BRENTWOOD, Tenn., January 13, 2020 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today...

IMAC Initiates Sale of BioFirma Subsidiary–IMAC Will Retain Long-Term Supply Agreement at Discount

BRENTWOOD, Tenn., November 12, 2019 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC) (the “Company” or “IMAC”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of...
IMAC Regeneration Centers Recognized as a Participant Provider in the U.S. Dept. of Veterans’ Affairs Community Care Network

IMAC Regeneration Centers Recognized as a Participant Provider in the U.S. Dept. of Veterans’ Affairs Community Care Network

IMAC Regeneration Centers Will Provide Veterans with the Opportunity to Supplement Their Healthcare within an Established Network of Civilian Care Providers BRENTWOOD, Tenn., November 5, 2019 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of...